Hepatitis B: improved antivirals and disease awareness drive rapid market growth

Fuelled by an increasing disease awareness, the growing use of new, expensive drugs as well as combination therapy, the hepatitis B drugs market, valued at $431m in 2006 across the seven major markets, will nearly triple in size to reach around $1.25 billion by 2016. However, between 2011 and 2016, further market growth will be hampered by patent expiries and the subsequent launch of cheap generics, as well as by the impact of vaccination.

Source: Datamonitor, "Commercial and Pipeline Insight: Hepatitis B - Improved antivirals drive rapid market growth" (DMHC2338)

Source: Datamonitor, "Commercial and Pipeline Insight: Hepatitis B - Improved antivirals drive rapid market growth" (DMHC2338)